GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company, today highlighted the expanding strategic relevance of its Gedeptin immuno-oncology program within the evolving landscape of combination immunotherapy and checkpoint inhibitor enhancement. The company believes Gedeptin's unique mechanism of localized tumor destruction combined with immune activation positions it to address immunologically cold tumors, which are often resistant to checkpoint inhibitors.
Checkpoint inhibitors targeting PD-1 and PD-L1 have transformed cancer treatment, but many solid tumors remain insufficiently responsive due to immune-suppressive tumor microenvironments, inadequate immune-cell infiltration, and incomplete tumor antigen recognition. Oncologists are increasingly focusing on combination approaches to improve response rates and extend durability of benefit. David Dodd, Chairman and CEO of GeoVax, stated, 'Modern immuno-oncology is increasingly shifting toward combination strategies designed to improve the effectiveness of checkpoint inhibitors across broader patient populations. We believe Gedeptin aligns directly with this trend by functioning not simply as a localized tumor therapy, but as a potential immune-sensitization platform.'
Gedeptin's platform features a tumor-agnostic mechanism of action independent of tumor histology or proliferation rate, a strong bystander effect that destroys neighboring tumor cells even when only a fraction are directly transduced, tumor microenvironment remodeling and immune activation, potential checkpoint sensitization supporting combination strategies with PD-1 and PD-L1 inhibitors, and compatibility with image-guided and intratumoral delivery approaches across multiple solid tumor settings.
GeoVax's lead development focus for Gedeptin is a planned neoadjuvant combination study in recurrent head and neck squamous cell carcinoma (HNSCC), evaluating intratumoral Gedeptin together with PD-1 targeting immunotherapy in patients eligible for curative-intent surgery. The study is expected to evaluate pathologic response, immune biomarker modulation, and early event-free survival signals. Mr. Dodd added, 'The oncology field is increasingly recognizing that durable checkpoint inhibitor responses may require direct modulation of the tumor microenvironment in addition to checkpoint blockade alone.'
Beyond head and neck cancer, GeoVax believes Gedeptin may have broader applicability across solid tumors characterized by established checkpoint inhibitor treatment paradigms, incomplete response durability, immunologically suppressed tumor microenvironments, and at least one lesion amenable to intratumoral or image-guided delivery. Potential future tumor targets under evaluation include melanoma, triple-negative breast cancer, cutaneous malignancies, and additional metastatic solid tumor settings.
Gedeptin is GeoVax's proprietary gene-directed enzyme prodrug therapy (GDEPT) platform. It uses a non-replicating adenoviral vector to deliver purine nucleoside phosphorylase (PNP) into tumor tissue. Following administration of fludarabine, the PNP enzyme converts the prodrug into a potent localized cytotoxic agent that destroys tumor cells while generating immune-activating signals. GeoVax is advancing development plans to evaluate Gedeptin in combination with immune checkpoint inhibitors, including pembrolizumab, with the goal of amplifying anti-tumor immune activation and broadening therapeutic applicability across multiple solid tumor indications.
For more information about GeoVax and its programs, visit www.geovax.com.
